All In Biotech

NDA 018484 · Pfizer

Prostin Vr Pediatric

Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Oct 16, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

145

40 Phase 3, 8 recruiting

FAERS reports

1,585

1,454 serious, 228 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediately available.

What it is approved for

From the label in effect Aug 17, 2026.

INDICATIONS AND USAGE PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 10, 1987 Supplement 5 · Efficacy
  • Oct 16, 1981 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • PROSTIN VR PEDIATRIC · ALPROSTADIL 0.5MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.

All 145 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use126
  • drug ineffective124
  • haemoglobin decreased82
  • lymphocyte count decreased79
  • pyrexia77
  • diarrhoea70
  • cardiac failure64
  • blood urea increased59
  • condition aggravated55
  • anaemia54
  • blood glucose increased54
  • neutrophil count increased54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200564
200672
200741
200862
200931
201053
201198
201266
201335
201417
201560
2016107
2017155
201894
2019115
202084
202186
202260
202346
202474
202557
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 197 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.